Principles of Post-Trial Responsibilities: Continued Access to an Investigational Medicine

The Multi-Regional Clinical Trials Center of Brigham and Women’s Hospital and Harvard (MRCT Center) Post-Trial Responsibilities: Continued Access to an Investigational Medicine Framework outlines a case-based, principled, stakeholder approach to evaluate and guide ethical responsibilities to provide continued access to an investigational medicine at the conclusion of a patient’s participation in a clinical trial. The foundation of this guidance document is summarized in 12 principles:

1. Post-trial responsibilities to a research participant (patient) at the end of participation in a clinical trial are shared among all stakeholders: sponsor, investigator, site, health care provider, health care system and the participant.

2. Provision of continued access is a bounded and not a limitless responsibility of any one stakeholder.

3. Responsibilities are generally equivalent whether the sponsor is a for-profit, not-for-profit or governmental agency, and whether the trial is conducted in a well- or low-resourced setting.

4. Provision of continued access must be fair and not inadvertently advantage some and harm others.

5. The plan to offer or not to offer continued access to an investigational medicine should be determined before a trial begins and appropriately communicated to investigators, ethics committees and participants.

6. If there is evidence of benefit exceeding risk, and importantly in settings of unmet medical need, continued access to a beneficial treatment should be considered for a participant.

7. Decisions regarding the provision of continued access to an investigational medicine or comparator to a participant are made on a case-by-case basis, influenced by the patient’s clinical condition, the benefit/risk assessment and response to the intervention, and what is known about the investigational medicine at the time of the decision.

8. Generally, informed consent for continued access should be solicited prior to provision of the medicine.

9. If continued access to an investigational medicine is offered, medical care and infrastructure specifically necessary for the appropriate provision of the investigational medicine must also be provided.

10. Continued access to an investigational medicine should always be provided under mechanisms that satisfy local regulatory requirements for investigational medicines.

11. The sponsor is responsible for continuously monitoring whether there is an ongoing unmet medical need for the investigational medicine during the clinical trial and drug development program.

12. For the health and safety of an individual participant, responsible transition from the investigational medicine to other appropriate care may be, and is often, necessary.
Continued Access Criteria

The sponsor and the investigator should weigh a number of interdependent criteria to inform decisions about the provision of continued access at both a Study Program and Individual Participant level. These criteria include:

1) **Study Program Level (Sponsor)**
   a. The disease under study is serious or life-threatening and/or the research participant could be adversely impacted if the medicine were to be discontinued;
   b. The investigational medicine addresses an unmet medical need in that there are no suitable therapeutic alternatives available to participants;
   c. There is no alternative access to the investigational medicine;
   d. The provision of continued access to the investigational medicine will not affect the viability of the research or the ability to complete the trial or other trials being conducted to develop the new medicine; and
   e. After data lock and analysis of the results, the overall study population benefit/risk assessment is known.

2) **Individual Participant Level (Investigator)**
   a. The eligible participant has completed the clinical trial protocol; and
   b. There is demonstrable evidence of benefit exceeding risk for an individual participant as determined by the investigator.
**Stages of Continued Access**

There are five stages during a clinical trial when continued access needs to be considered either at a Study Program (i.e., relative to the medicine and disease/condition under study) and/or Individual (i.e., relative to the individual participant) Level.

**Stage 1: Study Planning**

At the Study Program Level, the sponsor is responsible for planning before the trial begins. The sponsor should evaluate whether it is possible, in principle, that research participants will meet the criteria for continued access given the drug and disease/condition under study. If so, the sponsor should develop a plan in collaboration with relevant stakeholders, including establishing criteria for when a patient should be offered continued access when transitioned to another mechanism of access or to other alternatives. In multinational clinical trials, national legislation and local health care capabilities should be considered.

**Stage 2: Monitoring of available alternatives**

At the Study Program Level, the sponsor is responsible for ongoing monitoring throughout the course of the clinical study and drug development program to assess whether an unmet medical need persists that requires continued access to the investigational medicine. Other alternatives may become available that modify or eliminate the ethical justification to provide continued access.

**Stage 3: Decision Point 1**

At the Individual Participant level, the investigator is responsible for the first operative decision. At the participant’s last patient visit, the investigator evaluates and communicates (to the patient and sponsor) whether the individual’s benefit/risk assessment warrants continued access to the intervention(s) received during the trial (investigational medicine or comparator, and associated medical care) in accordance with Study Program planning. In some trial designs, where it is not possible to know if the participant has had benefit at the last visit (e.g. in asymptomatic condition where the endpoint is prevention, or in trials in which the endpoint is progression-free survival etc.), there would be no rationale to continue therapy after completion of the trial unless the results are known.

**Stage 4: Decision Point 2**

At the Study Program Level, the sponsor is responsible for a second operative decision. After database lock and data analysis, the sponsor evaluates whether the overall study population benefit/risk assessment warrants ongoing continued access to the intervention or, in some cases, offering all participants access to the intervention. In others, safety concerns or lack of efficacy may warrant reconsideration of the initial decision to provide continued access.

**Stage 5: Transition**

At the Individual Participant level, the investigator is responsible for a third operative decision as to whether and when participants should be transitioned off the intervention. Events such as the commercial availability of the investigational medicine, other satisfactory alternatives for treatment (see Stage 2), the participant no longer requiring treatment, the medicine’s lack of efficacy, or the occurrence of adverse events may trigger a transition decision. These possibilities, and the timing thereof, should be outlined in the informed consent to the trial.
Post-Trial Responsibilities Workgroup
Co-Chairs: Barbara E. Bierer and Luann Van Campen

Carmen Aldinger, MRCT Center
Mark Barnes, MRCT Center, Ropes and Gray LLP
Eileen Bedell, Takeda Pharmaceuticals International, Inc.
Barbara E. Bierer, MRCT Center, Brigham and Women’s Hospital, Harvard Medical School
Amanda Brown-Inz, MRCT Center
Rhea Coler, IDRI, Bill and Melinda Gates Foundation
Sonia Dainesi, Recepta Biopharma S.A.; formerly UCB Biopharma S.A., Brazil
Ricardo Eccard da Silva, ANVISA, Brazil
Pamela Gavin, National Organization for Rare Disorders
Robin Gibbs, Takeda Pharmaceuticals International, Inc.
Kate Heffernan, Verrill Dana LLP
Deborah Henderson, Merck & Co., Inc.
Joan Herbert, MMV, Bill and Melinda Gates Foundation
Patrick Kelly, Takeda Pharmaceuticals International, Inc.
Ariella Kelman, Genentech, Inc.
Laurie Letvak, Novartis International AG
Rebecca Li, MRCT Center, Brigham and Women’s Hospital, Harvard Medical School
Susan Manoff, Merck & Co., Inc.
Ignacio Mastroelo, FLACSO Bioethics Program, Argentina

Lindsay McNair, WIRB-Copernicus Group
Ramadhan Abdullah Noor, Harvard T.H. Chan School of Public Health
Ellie Okada, Boston Cancer Policy Institute
Wellington Oyibo, University of Lagos, Nigeria
Usharani Pingali, Nizam’s Institute of Medical Sciences, Hyderabad, India
Wasana Prasitsuebsai, GlaxoSmithKline; formerly HIV Nederland Australia Thailand
Juliana Rossi, Eli Lilly and Company, Brazil
Beth Roxland, Johnson & Johnson
Jessica Scott, GlaxoSmithKline
Seema Shah, National Institutes of Health
Lana Skirboll, Sanofi
Sheldon Sloan, Johnson and Johnson
Hans Spiegel, Henry M. Jackson Foundation for the Advancement of Military Medicine
Walter Straus, Merck & Co., Inc.
Jeremy Sugarman, Johns Hopkins Berman Institute of Bioethics
Jocelyn Ulrich, PhRMA
Luann Van Campen, Eli Lilly and Company
Daniel Wang, Queen Mary University of London, United Kingdom
Jayne Ware, Merck & Co., Inc.
Mitchell Warren, AVAC
Marc Wilenzick, International AIDS Vaccine Initiative